Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland
Author(s)
Witold Owczarek, Prof1, Irena Walecka-Herniczek, Prof2, Gerald Waligora, MSc1, Michal Pochopien, MSc, PhD3, Anna Lanecka, MSc4, Michal Gorecki, MSc4.
1Military Institute of Medicine, Warsaw, Poland, 2National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, 3Clever-Access, Paris, France, 4Clever-Access, Krakow, Poland.
1Military Institute of Medicine, Warsaw, Poland, 2National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, 3Clever-Access, Paris, France, 4Clever-Access, Krakow, Poland.
OBJECTIVES: This study aimed to assess the real-world effectiveness of biologic treatments for moderate-to-severe atopic dermatitis in Poland.
METHODS: A comprehensive dataset from the B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)” drug program of 2,319 patients treated between 2022 and 2025, was analysed. The dataset provided patient characteristics such as demographic information and dates of qualification to the program, together with counselling visit dates, medications used, and health indices at the counselling visits. The effectiveness of five biologics, namely abrocitinib, baricitinib, dupilumab, tralokinumab, and upadacitinib, was assessed with proportion of patients reaching 75% improvement in the Eczema Area and Severity Index (EASI75) and proportion of 0 or 1 scores on Dermatology Life Quality Index (DLQI 0/1).
RESULTS: After 16 weeks, the percentage of patients achieving EASI75 ranged from 69% (baricitinib) to 81% (tralokinumab). After 44 weeks, this percentage ranged from 75% (abrocitinib) to 100% (baricitinib). However, only 4 measurements for abrocitinib and 13 for baricitinib were available from this period. The data for DLQI 0/1 showed greater span of the results. After 16 weeks, the highest outcome was noted for abrocitinib: 46%. Dupilumab scored the lowest result, equal to 26%. After 44 weeks the results for DLQI 0/1 varied from 33% for tralokinumab to 75% for abrocitinib, although the result for abrocitinib was derived based on 4 measurements.
CONCLUSIONS: In real-world settings in Poland, different biologic agents show high, but differing effectiveness in treating moderate-to-severe atopic dermatitis. The data from the drug program indicate similar effectiveness across all included treatments in EASI75 and varying results in DLQI 0/1 response.
METHODS: A comprehensive dataset from the B.124 “Treatment of patients with atopic dermatitis (ICD-10: L20)” drug program of 2,319 patients treated between 2022 and 2025, was analysed. The dataset provided patient characteristics such as demographic information and dates of qualification to the program, together with counselling visit dates, medications used, and health indices at the counselling visits. The effectiveness of five biologics, namely abrocitinib, baricitinib, dupilumab, tralokinumab, and upadacitinib, was assessed with proportion of patients reaching 75% improvement in the Eczema Area and Severity Index (EASI75) and proportion of 0 or 1 scores on Dermatology Life Quality Index (DLQI 0/1).
RESULTS: After 16 weeks, the percentage of patients achieving EASI75 ranged from 69% (baricitinib) to 81% (tralokinumab). After 44 weeks, this percentage ranged from 75% (abrocitinib) to 100% (baricitinib). However, only 4 measurements for abrocitinib and 13 for baricitinib were available from this period. The data for DLQI 0/1 showed greater span of the results. After 16 weeks, the highest outcome was noted for abrocitinib: 46%. Dupilumab scored the lowest result, equal to 26%. After 44 weeks the results for DLQI 0/1 varied from 33% for tralokinumab to 75% for abrocitinib, although the result for abrocitinib was derived based on 4 measurements.
CONCLUSIONS: In real-world settings in Poland, different biologic agents show high, but differing effectiveness in treating moderate-to-severe atopic dermatitis. The data from the drug program indicate similar effectiveness across all included treatments in EASI75 and varying results in DLQI 0/1 response.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD22
Topic
Clinical Outcomes, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Biologics & Biosimilars, Sensory System Disorders (Ear, Eye, Dental, Skin)